On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns ...

BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

Chester County Futures (CCF), in collaboration with Globus Medical, recently provided a transformative learning experience ...

Globus Medical seems to be reverting to form, reporting a big jump in operating profit and profit margin for Q1, 2025. Here ...

Globus Medical, Inc. (NYSE:GMED) just released its latest quarterly report and things are not looking great. It wasn't a great result overall - while revenue fell marginally short of analyst ...

Across the recent three months, 6 analysts have shared their insights on Globus Medical GMED, expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

Globus Medical (GMED) came out with quarterly earnings of $0.68 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.72 per share a year ago. These ...

Globus Medical reported its financial results for Q1 2025, revealing a miss on both earnings and revenue forecasts. The company posted an earnings per share (EPS) of $0.68, falling short of the ...

AUDUBON, Pa. (AP) — AUDUBON, Pa. (AP) — Globus Medical Inc. (GMED) on Thursday reported first-quarter earnings of $75.5 million. On a per-share basis, the Audubon, Pennsylvania-based company ...